Cadrenal Therapeutics (NASDAQ: CVKD) is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral anticoagulant to prevent heart attacks, strokes & deaths due to blood clots in patients with rare CV conditions (LVAD, ESKD + AFib, APS).